Literature DB >> 9477048

Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate.

J B Streisand1, M A Busch, T D Egan, B G Smith, M Gay, N L Pace.   

Abstract

BACKGROUND: The pharmacokinetics of a single dose (15 microg/kg) of oral transmucosal fentanyl citrate (OTFC) have been characterized. A range of doses may eventually be used in clinical practice. The goal of this study was to determine if the pharmacokinetics of OTFC are dose proportional for doses ranging from 200 to 1,600 microg.
METHODS: Twelve healthy male volunteers were studied on four different occasions, receiving 200, 400, 800, and 1,600 microg OTFC in a double-blind, randomized protocol. Venous blood samples were collected at selected times during and after dosing for a 24-h period and assayed for fentanyl using a radioimmunoassay. Maximum concentration, time to maximum concentration, area under the curve, and elimination half-life were determined for each dose administered. In addition, respiratory rate, need for verbal prompting to breathe, and supplemental oxygen requirements were noted.
RESULTS: Mean fentanyl concentration time curves were similarly shaped with increasing doses. Both peak concentrations and area under the curve increased linearly with an increase in dose, whereas time to reach peak serum concentrations did not vary significantly between doses. Except for the 200-microg dose, the apparent elimination half-life remained relatively constant (358-386 min). The incidence of low respiratory rate, supplemental oxygen requirement, and number of breathing prompts significantly increased with increasing doses.
CONCLUSIONS: Oral transmucosal fentanyl citrate exhibits dose-proportional pharmacokinetics over the dose range of 200-1,600 microg.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477048     DOI: 10.1097/00000542-199802000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  17 in total

1.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 2.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.

Authors:  Naohito Shimoyama; Ikuo Gomyo; Nobuyuki Katakami; Masakuni Okada; Nobuyuki Yukitoshi; Eri Ohta; Megumi Shimoyama
Journal:  Int J Clin Oncol       Date:  2014-05-20       Impact factor: 3.402

5.  Oral transmucosal fentanyl pretreatment for outpatient general anesthesia.

Authors:  P A Moore; M A Cuddy; J A Magera; A C Caputo; A H Chen; L A Wilkinson
Journal:  Anesth Prog       Date:  2000

6.  Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.

Authors:  B Lennernäs; T Hedner; M Holmberg; S Bredenberg; C Nyström; H Lennernäs
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 7.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  [Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS)].

Authors:  R Zarth; M Ehmer; H-B Sittig
Journal:  Schmerz       Date:  2007-11       Impact factor: 1.107

Review 9.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 10.  Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.

Authors:  Kyriaki Mystakidou; Eleni Tsilika; Marinos Tsiatas; Lambros Vlahos
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.